Analyst Conference Summaries

Biotechnology Investor Aids

Epizyme
EPZM

conference date: May 10, 2022 @ 5:30 AM Pacific Time

Epizyme Stock Soars 60% on Ipsen Acquisition [June 32, 2020 @ Seeking Alpha]

Epizyme Comeback Is Likely, Price Makes It A Buy by William Meyers [March 30, 2021 @ Seeking Alpha]

Epizyme A Buy For Tazverik And Epigenetic Platform [July 1, 2020 @ Seeking Alpha]

Epizyme A Buy On Firmer Tazemetostat Timeline by William Meyers [June 5, 2019 @ Seeking Alpha]

Epizyme As A Strategic Acquisition For Epigenetic Therapies by William Meyers [March 6, 2019 @ Seeking Alpha]

2022
Epizyme
Q1 2022
     
May 10, 2022      
2021
Epizyme
Q1 2021
Epizyme
Q2 2021
Epizyme
Q3 2021
Epizyme
Q4 2021
May 6, 2021 Aug. 9, 2021 Nov. 9, 2021 March 1, 2022
2020
Epizyme
Q1 2020
Epizyme
Q2 2020
Epizyme
Q3 2020
Epizyme
Q4 2021
May 4, 2020 Aug. 4, 2020 Nov. 6, 2020 Feb. 23, 2021
2019
Epizyme
Q1 2019
Epizyme
Q2 2019
Epizyme
Q3 2019
press release
Epizyme
Q4 2019
May 6, 2019 August 9, 2019 Oct. 30, 2019 Feb. 24, 2020
2018
Epizyme
Q4 2018
May 8, 2018
Aug. 2, 2018
Nov. 2, 2018
Feb. 26, 2019
2017
May 8, 2017
Aug. 4, 2017
Nov. 1, 2017
Mar. 13, 2018  
2016
05/09/2016
08/08/2016
11/03/2016 
03/09/2017
2015
na
Q2 na
Q1
08/06/2015
11/09/2015
03/09/2016

Older News:

Epizyme Should Pop When Tazemetostat Hold Clears by William Meyers [August 23, 2018 @ Seeking Alpha]

Epizyme Partnership with Celgene [July 13, 2015 @ Seeking Alpha]

Epizyme (EPZM) is a clinical-stage biotechnology pharmaceuticals comapny.

Epizyme web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 MCHP
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 TTPH
 VBLT
 VRTX
 VSTM
 WBA

   
 

Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2022 William P. Meyers